Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Henlius Biotech Approved to Launch Herceptin Biosimilar in China

publication date: Aug 17, 2020

Shanghai Henlius Biotech, a Fosun Pharma offspring, has been approved to launch its Herceptin (trastuzumab) biosimilar in China. It is approved to treat HER2-positive early breast cancer, HER2-positive metastatic breast cancer and HER2-positive metastatic gastric cancer. Henlius said the biosimilar will be automatically listed on China's National Reimbursement Drug List, along with Herceptin. Last month, Henlius was approved for European use in the same indications. More details....

Stock Symbols: (HK: 2696) (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.